STAT3 pathway and β-catenin signaling are frequently dysregulated in breast cancer, contributing to cancer stem cells (CSCs)-associated tumor initiation, angiogenesis, metastasis, therapy resistance, and tumor relapse [13,14]. Here, STAT3 is linked to breast carcinoma.